ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 278 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $29,695,973 | +118.2% | 1,105,172 | +189.5% | 0.00% | +200.0% |
| Q2 2023 | $13,611,457 | +12.6% | 381,701 | -19.8% | 0.00% | 0.0% |
| Q1 2023 | $12,084,482 | -55.3% | 475,767 | -28.6% | 0.00% | -66.7% |
| Q4 2022 | $27,025,574 | +67.9% | 666,311 | +36.8% | 0.00% | +50.0% |
| Q3 2022 | $16,098,000 | -24.7% | 487,031 | -19.8% | 0.00% | 0.0% |
| Q2 2022 | $21,383,000 | -43.8% | 607,288 | -26.6% | 0.00% | -50.0% |
| Q1 2022 | $38,030,000 | -3.7% | 826,932 | +38.8% | 0.00% | 0.0% |
| Q4 2021 | $39,494,000 | +2.7% | 595,689 | -3.2% | 0.00% | 0.0% |
| Q3 2021 | $38,437,000 | -17.8% | 615,672 | +9.0% | 0.00% | -20.0% |
| Q2 2021 | $46,769,000 | +17.4% | 564,710 | -6.0% | 0.01% | +25.0% |
| Q1 2021 | $39,843,000 | -3.3% | 600,866 | +11.9% | 0.00% | -20.0% |
| Q4 2020 | $41,200,000 | +83.3% | 536,920 | +2.8% | 0.01% | +66.7% |
| Q3 2020 | $22,481,000 | +3.2% | 522,089 | +3.5% | 0.00% | 0.0% |
| Q2 2020 | $21,794,000 | +39.8% | 504,628 | -6.8% | 0.00% | 0.0% |
| Q1 2020 | $15,584,000 | -40.3% | 541,670 | +31.7% | 0.00% | -25.0% |
| Q4 2019 | $26,096,000 | +52.9% | 411,437 | -32.1% | 0.00% | +33.3% |
| Q3 2019 | $17,072,000 | +2.3% | 605,811 | -3.8% | 0.00% | 0.0% |
| Q2 2019 | $16,683,000 | +19.1% | 629,555 | -17.6% | 0.00% | +50.0% |
| Q1 2019 | $14,012,000 | +237.8% | 763,634 | +128.7% | 0.00% | +100.0% |
| Q4 2018 | $4,148,000 | +74.0% | 333,938 | +168.5% | 0.00% | – |
| Q3 2018 | $2,384,000 | +137.9% | 124,354 | +68.8% | 0.00% | – |
| Q2 2018 | $1,002,000 | +728.1% | 73,657 | +339.8% | 0.00% | – |
| Q1 2018 | $121,000 | +128.3% | 16,748 | +15.8% | 0.00% | – |
| Q4 2017 | $53,000 | -34.6% | 14,463 | -22.5% | 0.00% | – |
| Q3 2017 | $81,000 | +42.1% | 18,670 | -46.7% | 0.00% | – |
| Q2 2017 | $57,000 | +72.7% | 35,060 | +91.8% | 0.00% | – |
| Q1 2017 | $33,000 | +65.0% | 18,278 | +42.8% | 0.00% | – |
| Q4 2016 | $20,000 | -48.7% | 12,797 | +142.5% | 0.00% | – |
| Q3 2016 | $39,000 | -18.8% | 5,278 | -40.7% | 0.00% | – |
| Q2 2016 | $48,000 | – | 8,902 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,264 | $54,392,000 | 33.22% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $216,228,000 | 28.00% |
| L1 Capital Pty Ltd | 296,024 | $19,629,000 | 4.93% |
| Aquilo Capital Management, LLC | 407,926 | $27,050,000 | 4.89% |
| Evolutionary Tree Capital Management, LLC | 72,948 | $4,837,000 | 2.86% |
| ACUTA CAPITAL PARTNERS, LLC | 108,000 | $7,161,000 | 2.58% |
| First Light Asset Management, LLC | 536,836 | $35,598,000 | 2.36% |
| Parkman Healthcare Partners LLC | 70,089 | $4,648,000 | 1.08% |
| Hood River Capital Management LLC | 357,082 | $23,678,000 | 0.76% |
| Vanguard Capital Wealth Advisors | 11,099 | $703,565,000 | 0.60% |